CDRO
Codere Online Luxembourg, S.A.
There isn't enough reported data to score CDRO yet.
LCID
Lucid Group, Inc.
LCID lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
CDRO Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Healthy | |
| Unavailable | |
| Unavailable |
CDRO's profitability is currently healthy. There isn't enough data to rate its revenue, cash flow and balance sheet.
LCID Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
LCID's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
CDRO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 72x | $7.22 | -15% |
| Fair | 79x | $7.94 | -7% |
| Current | 85x | $8.54 | — |
| Expensive | 89x | $8.89 | +4.1% |
Historical ranges are pointers, not guarantees.
CDRO's PE is 85x, but its earnings don't support one, so it isn't a reliable read right now.
LCID PE Valuation
LCID has no meaningful PE right now: it lost money over the past year.
CDRO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for CDRO, with profitability improving.
LCID Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect LCID's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
CDRO Earnings Per Share
CDRO and LCID do not have enough comparable growth data to identify a winner.
LCID Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$13.08 | -$2.57 |
| Q2 2026 | -$13.65 | -$2.35 |
| Q1 2026 | -$13.15 | -$1.25 |
| Q4 2025 | -$12.09 | +$0.41 |
| Q3 2025 | -$10.51 | +$2.49 |
| Q2 2025 | -$11.30 | +$0.40 |
| Q1 2025 | -$11.90 | +$0.40 |
| Q4 2024 | -$12.50 | +$1.10 |
LCID is still losing money, but less than at its worst: $13.08 per share over the past year, against $16.50 at its worst in mid-2023.
CDRO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2024 | $109.5M | +13% |
| Q2 2024 | $56.7M | +37% |
| Q1 2024 | $56.7M | +37% |
| Q4 2023 | $96.7M | -25% |
| Q4 2022 | $128.6M | +44% |
| Q4 2021 | $89.2M | +296% |
CDRO has the edge over LCID in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2024 | 2.7% | +18 points |
| Q2 2024 | 1.6% | +17 points |
| Q1 2024 | 1.6% | +50 points |
| Q4 2023 | -4% | +85 points |
| Q2 2023 | -15% | +5.7 points |
| Q1 2023 | -15% | +5.7 points |
| Q4 2022 | -48% | -38 points |
| Q4 2021 | -89% | -62 points |
CDRO's operating margin was 2.7% last quarter, up 18 points from the same quarter a year ago, near the top of its range since 2020.
LCID Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $350.3M | +4.1% |
| Q2 2026 | $405.3M | +56% |
| Q1 2026 | $282.5M | +20% |
| Q4 2025 | $522.7M | +123% |
| Q3 2025 | $336.6M | +68% |
| Q2 2025 | $259.4M | +29% |
| Q1 2025 | $235M | +36% |
| Q4 2024 | $234.5M | +49% |
LCID's revenue has grown year over year for 11 quarters in a row: $350M last quarter, up 4.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -245% | +35 points |
| Q2 2026 | -267% | +43 points |
| Q1 2026 | -350% | -56 points |
| Q4 2025 | -204% | +109 points |
| Q3 2025 | -280% | +105 points |
| Q2 2025 | -310% | +83 points |
| Q1 2025 | -294% | +128 points |
| Q4 2024 | -313% | +156 points |
LCID's operating margin was −245% last quarter, up 35 points from the same quarter a year ago, near the top of its range since 2020.
CDRO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2024 | -$243.8K | -$239.7K |
| Q1 2024 | -$243.8K | -$239.7K |
CDRO's free cash flow has turned negative after years in the green: −$495,966 over the past year.
LCID Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1B | -$84.2M |
| Q2 2026 | -$1.5B | -$463.2M |
| Q1 2026 | -$1.4B | -$849M |
| Q4 2025 | -$1.2B | -$417.1M |
| Q3 2025 | -$955.5M | -$333M |
| Q2 2025 | -$1B | -$271.6M |
| Q1 2025 | -$589.9M | +$125.1M |
| Q4 2024 | -$824.8M | -$77.6M |
LCID has burned cash in almost every quarter: −$5.2B over the past year, against −$3.4B the year before.
CDRO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +24K shares |
| 1 year | +0.5% | +232K shares |
CDRO has the edge over LCID on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2024 | — |
| Q1 2024 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
LCID Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.3% | +12.5M shares |
| 1 year | +26% | +82.4M shares |
| 3 years | +73% | +166M shares |
LCID has 395M diluted shares, up 26% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | $2.2M |
| Q1 2020 | — |
CDRO Net Leverage
LCID Net Leverage
LCID's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
CDRO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.1 | Neutral |
| Stochastic | 15.8 | Oversold |
CDRO's weekly RSI is 42 (neutral) and its Stochastic is 16 (oversold).
LCID Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.9 | Neutral |
| Stochastic | 7.1 | Oversold |
LCID's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
CDRO PE vs Consumer Cyclical Sector
| Metric | CDRO | Sector median | Relative |
|---|---|---|---|
| PE | 85x | 18x | 372% above |
| PE % | 65 | 51 | 14 pts above |
CDRO is trading at 85x earnings, a 372% premium to the Consumer Cyclical sector's median of 18x, though its earnings don't support one.
LCID PE vs Consumer Cyclical Sector
LCID has no meaningful PE right now: it lost money over the past year.
CDRO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $9.14 | 6.6% below |
| 20 week MA | $9.18 | 7% below |
| 50 week MA | $8.78 | 2.7% below |
| 100 week MA | $8.07 | 5.8% above |
| 200 week MA | $6.57 | 30% above |
CDRO has the edge over LCID on trend strength, trading above more of its moving averages.
LCID Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.53 | 7.9% below |
| 20 week MA | $4.88 | 33% below |
| 50 week MA | $7.33 | 56% below |
| 100 week MA | $15.4 | 79% below |
| 200 week MA | $31.9 | 90% below |
LCID is in a downtrend: it's below all five of its weekly moving averages, and 90% below its 200-week average.
CDRO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $10.1 | $6.25 | -38% |
| 2022 | $6.25 | $2.53 | -60% |
| 2023 | $2.53 | $2.94 | +16% |
| 2024 | $2.94 | $6.77 | +130% |
| 2025 | $6.77 | $8.09 | +19% |
| 2026 YTD | $8.09 | $8.54 | +5.6% |
CDRO has the edge over LCID on returns for 2026, with the stronger performance.
LCID Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $98.9 | $100.4 | +1.5% |
| 2021 | $100.4 | $376.4 | +275% |
| 2022 | $376.4 | $67.0 | -82% |
| 2023 | $67.0 | $42.1 | -37% |
| 2024 | $42.1 | $32.0 | -24% |
| 2025 | $32.0 | $11.4 | -64% |
| 2026 YTD | $11.4 | $3.25 | -72% |
LCID has finished four years in a row lower, and it's down 72% so far in 2026.